YOU ARE CORDIALLY INVITED TO ATTEND A VIRTUAL SPEAKER PROGRAM

Protecting Patients with NERLYNX
the only HER2-directed small molecule approved by the FDA in both eBC and mBC

PRESENTED BY:
ANNE O’DEA, MD
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
PRAIRIE VILLAGE, KS

PROGRAM HOST:
AMY ISENOGLE

PROGRAM INFORMATION:
TUESDAY, MAY 19, 2020
12:00PM EST
Web URL: http://www.medpt.com/guestattend
Event Number: 43330K

Please contact the MedPoint Help Desk if you have any questions at HCGservices@medpt.com or 800-765-0487.

PLEASE REGISTER ONLINE AT:
PUMAREG.TSGMEDDED.COM
Enter Event Code: 51251

New Jersey, Minnesota, Vermont, the Department of Defense, and the Department of Veterans Affairs have restrictions on receiving in-kind benefits (e.g., meals, paid parking) at company-sponsored events. For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Puma Biotechnology policies may restrict you from consuming any portion of the Puma Biotechnology-sponsored meal at this program or from receiving any other in-kind benefit from Puma Biotechnology (e.g., paid parking) in connection with the program.

This program is sponsored by Puma Biotechnology, Inc.
This is not an independent educational program, and no CME credits will be provided.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:

• NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

• NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

Please see Important Safety Information on reverse side and accompanying Full Prescribing Information including Patient Information
IMPORTANT SAFETY INFORMATION

NERLYNX® (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

• As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
• In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

• Diarrhea: Aggressively manage diarrhea occurring despite recommended prophylaxis with additional antidiarrheals, fluids, and electrolytes as clinically indicated. Withhold NERLYNX in patients experiencing severe and/or persistent diarrhea. Permanently discontinue NERLYNX in patients experiencing Grade 4 diarrhea or Grade ≥ 2 diarrhea that occurs after maximal dose reduction.
• Hepatotoxicity: Monitor liver function tests monthly for the first 3 months of treatment, then every 3 months while on treatment and as clinically indicated. Withhold NERLYNX in patients experiencing Grade 3 liver abnormalities and permanently discontinue NERLYNX in patients experiencing Grade 4 liver abnormalities.
• Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:

• NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.
• NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) and www.NERLYNX.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS:

• Gastric acid reducing agents: Avoid concomitant use with proton pump inhibitors. When patients require gastric acid reducing agents, use an H2-receptor antagonist or antacid. Separate NERLYNX by at least 3 hours with antacids. Separate NERLYNX by at least 2 hours before or 10 hours after H2-receptor antagonists.
• Strong CYP3A4 inhibitors: Avoid concomitant use
• Moderate CYP3A4 and P-glycoprotein (P-gp) dual inhibitors: Avoid concomitant use.
• Strong or moderate CYP3A4 inducers: Avoid concomitant use.
• P-glycoprotein (P-gp) substrates: Monitor for adverse reactions of narrow therapeutic agents that are P-gp substrates when used concomitantly with NERLYNX

USE IN SPECIFIC POPULATIONS:

• Lactation: Advise women not to breastfeed.

NERLYNX is a registered trademark of Puma Biotechnology, Inc.
©2019 Puma Biotechnology, Inc. All Rights Reserved. PRC-US-NER- 1437 03/20